共 70 条
[1]
Zachariae H(2002)Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study Acta Derm Venereol. 82 108-113
[2]
Zachariae R(2001)Physical and psychologic measures are necessary to assess overall psoriasis severity J Am Acad Dermatol. 45 72-76
[3]
Blomqvist K(2004)Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis J Investig Dermatol. 122 602-607
[4]
Davidsson S(2012)Who ordered that? The economics of treatment choices in medical care Handb Health Econ. 2 397-431
[5]
Molin L(2002)Unwarranted variations in healthcare delivery: implications for academic medical centres BMJ. 325 961-964
[6]
Mork C(2012)Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice Dermatology. 225 326-332
[7]
Kirby B(2015)Register-based evaluation of relative effectiveness of new therapies: biologics versus conventional agents in treatment of psoriasis in Sweden BioDrugs. 29 389-398
[8]
Richards HL(2007)PsoReg–the Swedish registry for systemic psoriasis treatment. The registry’s design and objectives Dermatology. 214 112-117
[9]
Woo P(2006)Psoriasis therapy in real life: the need for registries Dermatology. 213 327-330
[10]
Hindle E(1978)Severe psoriasis–oral therapy with a new retinoid Dermatologica. 157 238-244